LIST OF CITATIONS

Puneet Agarwal:

Hycienth Ahaneku:

Mohammad Azam:

John Barrett:

Ravi Bhatia:

Massimiliano Bonifacio:
- Bonifacio M, Binotto G, Maino E, et al. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced possibility of subsequent optimal response. Haematologica. 2015;100(8):e299-301
Dominique Bonnet:


Susan Branford:


Bing Z Carter:


Wenyong Chen:

- Wang Z, Chen CC, Chen WY. CD150− side population defines leukemia stem cells in a BALB/c mouse model of CML and is depleted by genetic loss of SIRT1. Stem Cells 2015, 33: 3437–3451
- Roth R, Wang Z, Chen WY. SIRT1 and LSD1 competitively regulate Ku70 functions in DNA repair and mutation acquisition in cancer cells. Oncotarget; 2016 June 30

Jorge Cortes:


Yashodhara Dasgupta:

Gwo-Jen Day:

Michael Deininger:

Marc Delord:
- Delord M, Genin E. Multiple imputation for competing risks regression with interval censored data journal of statistical computation and simulation. 2015

Young Rok Do:

Laura Eadie:
- Eadie LN, Hughes TP, White DL. The clinical significance of early imatinib induced ABCB1 overexpression in chronic phase CML patients: A TIDEL II sub-study. Blood. 2015;126(23):348
- Eadie LN, Saunders VA, Leclercq TM, et al. The allosteric inhibitor ABL001 is susceptible to resistance in vitro mediated by overexpression of the drug efflux transporters ABCB1 and ABCG2. Blood. 2015;126(23):4841
Anna Eiring:


Carlo Gambacorti-Passerini:


Stuart Goldberg:


- Goldberg SL, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood 2015; 126:1584 abstract

Elodie Grockowiak:

- Laperrousaz B, Jeanpierre S, Sagorny K et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPR1b overexpression. Blood. 2013 Nov 28;122(23):3767–77
François Guilhot:
- Guilhot F. Cytogenetic in CML: more important than you think. Blood 2016; 127: 2661-62

John Groffen:

Oliver Hantschel:

Nora Heisterkamp:

G. Vignir Helgason:

Andreas Hochhaus:


**Tessa Holyoake:**


**Tim P. Hughes:**


• Nievergall E, Reynolds J, Kok C, et al. TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia June 2016 30(6) 1263-1272

• Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. BLOOD 2016-01-694265

• Parker WT, Yeung DT, Yeoman AL, et al. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. BLOOD April 2016 Vol 127 1870 -1880


**Brian Huntly:**


• Fong CY, Gilan O, Huntly BIP et al. BET inhibitor resistance emerges from leukemia stem cells. Nature. 2015 Sep 24;525(7570):538-42


**Lorna Jackson:**


**Qian Jiang:**


• Jiang Q, Qin YZ, Lai YY, et al. Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance. Leuk Lymphoma. 2015 Jul;56(7):2075-81

Hagop Kantarjian


Dennis Dong Hwan Kim

• Ahn JS, Kim HJ, Kim YK. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype. Haematologica 2015;100(9):e351-3

Daniela Krause:
• Krause DS, Scadden DT. A hostel for the hostile: The stem cell niche in haematological neoplasms. Haematologica. 2015 Nov;100(11):1376-87


François-Xavier Mahon:


Giovanni Martinelli:


Michael Mauro:


Adam Mead:


• Wills QF, Mead AJ. Application of single-cell genomics in cancer: promise and challenges. Hum Mol Genet. 2015;24(R1):R74-84

Hind Medyouch:


Martin Müller:


Chinmay Rajiv Munje:


Markus Müschen:

Pratik Nagaria:

Rihab Nasr:

King Pan Ng:
- Chau BL, Ng KP, Li KK et al. RGG boxes within the TET/FET family of RNA-binding proteins are functionally distinct. Transcription. 2016: e1183071
- Ko TK, Chin HS, Chua CT et al. The BIM deletion polymorphism: a paradigm of a permissive interaction between germline and acquired TKI resistance factors in CML. Oncotarget, 2016; 7(3):2721-33

Danilo Perrotti:
Javier Pinilla-Ibarz:

- Fradley MG, Pinilla-Ibarz J. Arrhythmic complications of tyrosine kinase inhibitors. Future Cardiol 2015 Jul; 11: (4) 395-399

Katarzyna Piwocka:


Sabrina Pricl:


Stephane Prost:


Jerry Radich:


Feyruz Rassool:


• Pratik Nagaria, Carine Robert, et al. High-fidelity reprogrammed Human iPSCs have a high efficacy of DNA repair and resemble hESCs in their MYC transcriptional signature". In press Stem Cell International


Delphine Réa:


Anthony Rongvaux:


Philippe Rousselot:


Koji Sasaki:

Rahul Satija:

Susanne Saussele:

Mirl Schmionek:

Charles Schiffer:

Jan Jacob Schuringa:

Tomasz Skorski:

Simona Soverini:

Tomasz Stoklosa:

Ana Tari Ashizawa:

Daniel G. Tenen:

Hein Than:

• Than H, Chuah C, Ong ST. Molecular mechanism of TKI resistance and potential approaches to overcome resistance (Chapter) in molecular pathogenesis and treatment of chronic myelogenous leukaemia (Springer Japan 2016. ISBN 978-4-431-55713-5)

Luisa Tomasello:


Paolo Vigneri:


Wei Wang:


Claudia Waskow:


Robert S. Welner:


Deborah White:

• Nievergall E, Reynolds J, Kok CH, et al.; Predictive value of TGF- α and IL-6 plasma levels to identify CML patients that fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016 Jun;30(6):1263-72


Dominik Wolf:
• Rudolph J, Heine A, Quast T, et al. The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK. Leukemia. 2016 May 25
